Table 1.
Positive COVID-19 cases per IMD patients and percentage of asymptomatic, symptomatic, hospitalized, required intensive care, and died patients.
| Total IMD patients (n = 1058) n (%) | IMD diagnosis n | Positive COVID-19 cases n (%) | Asymptomatic n = 17 (13.7%) | Symptomatic n = 107 (86.2%) | Hospitalized n = 22 (17.7%) | Intensive care n = 10 (8%) | Deaths n = 3 (2.4%) |
|---|---|---|---|---|---|---|---|
| Intoxication Disorders 638 (60%) |
MMA (109) | 16 (15%) | 2 (12.5%) | 14 (87.5% | 7 (43.7%) | 3 (18.7%) | 2 (12.5%) |
| PA (33) | 3 (9%) | 0 | 3 (100%) | 3 (100%) | 3 (100%) | 0 | |
| IVA (34) | 4 (12%) | 0 | 4 (100%) | 0 | 0 | 0 | |
| GA-I (58) | 12 (21%) | 3 (25%) | 9 (75%) | 1 (8%) | 0 | 0 | |
| MSUD (78) | 8 (10%) | 1 (12.5%) | 7 (87.5%) | 1 (12.5%) | 0 | 0 | |
| ASA (49) | 7 (14%) | 0 | 7 (100%) | 2 (28.5%) | 2 (28.5%) | 0 | |
| CIT-I (30) | 0 (0%) | 0 | 0 | 0 | 0 | 0 | |
| HCU (85) | 12 (14%) | 0 | 12 (100%) | 2 (16.6%) | 0 | 0 | |
| PKU (99) | 13 (13%) | 5 (38%) | 8 (61.5%) | 0 | 0 | 0 | |
| TYR-I (45) | 7 (16%) | 1 (14.2%) | 6 (85.7%) | 0 | 0 | 0 | |
| TYR-II (18) | 0 (0) | 0 | 0 | 0 | 0 | 0 | |
| Carbohydrate Metabolism Disorders 197 (19%) |
GALT (58) | 7 (12%) | 1 (14.2%) | 6 (85.7%) | 0 | 0 | 0 |
| FBP1 (33) | 5 (15.15%) | 2 (40%) | 3 (60%) | 0 | 0 | 0 | |
| GSD-I (47) | 2 (4.25%) | 0 | 2 (100%) | 0 | 0 | 0 | |
| GSD-III (59) | 8 (13.5%) | 0 | 8 (100%) | 0 | 0 | 0 | |
| Energy Metabolism Disorders 181 (17%) |
BKT (23) | 2 (9%) | 0 | 2 (100%) | 0 | 0 | 0 |
| HMG (60) | 9 (15%) | 2 (22%) | 7 (77%) | 2 (22%) | 0 | 0 | |
| VLCADD (98) | 6 (6%) | 0 | 6 (100%) | 2 (33.3%) | 1 (16.6%) | 0 | |
| Complex Molecules Defects 42 (4%) |
MPS I-IV & VI) (42) |
3 (7%) | 0 | 3 (100%) | 2 (66.6%) | 1 (33.3%) | 1 (33.3%) |
Methylmalonic Acidemia (MMA), Propionic Acidemia (PA), Isovaloric Acidemia (IVA), Glutaric Aciduria type I (GA-I), Maple Syrup Urine Disease (MSUD), Argininosuccinic Aciduria (ASA), Citrullinemia type I (CIT-I), Homocysteinurea (HCU), Phenylketonuria (PKU), Tyrosinemia type I (TYR-I), Tyrosinemia type II (TYR-II); Beta-Ketothiolase deficiency (BKT), HMG-CoA lyase deficiency (HMG), Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD), Galactosemia (GALT), Fructose 1.6 bisphosphates deficiency (FBP1), glycogen storage disease type I (GSD-I), Glycogen Storage Disease type IIII (GSD-III), Mucopolysaccharidosis types (I-IV and VI) (MPS I-IV and VI).